Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.
Viruses typically elicit potent adaptive immune responses, and live-virus-based vaccines are among the most efficient human vaccines known. The mechanisms by which viruses stimulate adaptive immune responses are not fully understood, but activation of innate immune signaling pathways in the early phase of the infection may be of importance. In addition to stimulating immune responses to viral antigens expressed in infected cells, viruses can also provide adjuvant signals to coimmunized protein antigens. Using recombinant Semliki Forest virus (rSFV)-based vaccines, we show that rSFV potently enhanced antibody responses against coimmunized protein antigens in the absence of other exogenously added adjuvants. Elicitation of antibody responses against both virus-encoded antigens and coimmunized protein antigens was independent of the signaling via Toll-like receptors (TLRs) previously implicated in antiviral responses. In contrast, the adjuvant effect of rSFV on coimmunized protein was completely abolished in mice lacking the alpha/beta interferon (IFN-alpha/beta) receptor (IFN-AR1), demonstrating that IFN-alpha/beta signaling was critical for mediating this effect. Antibody responses directed against virus-encoded antigens were intact in IFN-AR1(-/-) mice, suggesting that other signals are sufficient to drive immune responses against virally encoded antigens. These data provide a basis for the adjuvant effect of rSFV and show that different signals are required to stimulate antibody responses to virally encoded antigens and to antigens administered as purified protein vaccines, together with viral particles.
Hidmark
Asa S
AS
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, S-171 77 Stockholm, Sweden.
Nordström
Eva K L
EK
Dosenovic
Pia
P
Forsell
Mattias N E
MN
Liljeström
Peter
P
Karlsson Hedestam
Gunilla B
GB
D000276:Adjuvants, Immunologic / Q000235:genetics / Q000494:pharmacology; D018354:Alphavirus Infections / Q000235:genetics / Q000276:immunology / Q000517:prevention & control; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology*; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D002460:Cell Line; D006224:Cricetinae; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology; D016899:Interferon-beta / Q000276:immunology; D051379:Mice; D018345:Mice, Knockout; D011817:Rabbits; D017471:Receptors, Interferon / Q000172:deficiency / Q000276:immunology; D012672:Semliki forest virus / Q000235:genetics / Q000276:immunology*; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000956:Antigens, Viral; D016898:Interferon-alpha; D017471:Receptors, Interferon; D014764:Viral Proteins; D014765:Viral Vaccines; D016899:Interferon-beta